
Andrea L Kwa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11941925/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2005, 49, 3624-3630.	3.2	198
2	Prevalence of Healthcare-Associated Infections and Antimicrobial Use Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National Point Prevalence Survey. Clinical Infectious Diseases, 2017, 64, S61-S67.	5.8	97
3	Polymyxin B versus colistin: an update. Expert Review of Anti-Infective Therapy, 2015, 13, 1481-1497.	4.4	80
4	In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore. PLoS ONE, 2011, 6, e18485.	2.5	55
5	The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection. Frontiers in Microbiology, 2020, 11, 1249.	3.5	52
6	Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B. PLoS ONE, 2011, 6, e28177.	2.5	51
7	Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrobial Resistance and Infection Control, 2015, 4, 2.	4.1	42
8	In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore. Journal of Antibiotics, 2009, 62, 675-679.	2.0	27
9	Impact of the COVID-19 pandemic on a tertiary care public hospital in Singapore: resources and economic costs. Journal of Hospital Infection, 2022, 121, 1-8.	2.9	25
10	Polymyxins: a review of the current status including recent developments. Annals of the Academy of Medicine, Singapore, 2008, 37, 870-83.	0.4	25
11	Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection. BMC Microbiology, 2022, 22, 13.	3.3	24
12	Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. Journal of Infection, 2015, 70, 309-311.	3.3	20
13	A multidisciplinary antimicrobial stewardship programme safely decreases the duration of broad-spectrum antibiotic prescription in Singaporean adult renal patients. International Journal of Antimicrobial Agents, 2016, 47, 91-96.	2.5	15
14	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1525-1537.	2.5	15
15	<i>In Vitro</i> Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Antimicrobial Agents and Chemotherapy, 2016, 60, 5238-5246.	3.2	14
16	Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
17	Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study. Antibiotics, 2020, 9, 451.	3.7	14
18	From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB). PLoS ONE, 2016, 11, e0158740.	2.5	13

Andrea L Kwa

#	Article	IF	CITATIONS
19	Rhodococcus equiPneumonia in a Patient with Human Immunodeficiency Virus: Case Report and Review. Pharmacotherapy, 2001, 21, 998-1002.	2.6	12
20	Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10
21	A procalcitonin-based guideline promotes shorter duration of antibiotic use safely in acute pancreatitis. Journal of Infection, 2014, 69, 412-415.	3.3	8
22	Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. Journal of Antimicrobial Chemotherapy, 2009, 63, 627-628.	3.0	6
23	Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. Infection and Drug Resistance, 2018, Volume 11, 1591-1596.	2.7	6
24	The impact of healthcare associated infections on mortality and length of stay in Singapore—A time-varying analysis. Infection Control and Hospital Epidemiology, 2020, 41, 1315-1320.	1.8	6
25	Estimating the excess bed days and economic burden of healthcare-associated infections in Singapore public acute-care hospitals. Infection Control and Hospital Epidemiology, 2021, , 1-4.	1.8	4
26	Implementing National Antimicrobial Stewardship Program (ASP): Our Singapore Story. Open Forum Infectious Diseases, 2016, 3, .	0.9	3
27	Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 719421.	3.9	3
28	Intravenous ceftaroline 200mg administered every 8h is safe and adequate for meticillin-resistant Staphylococcus aureus bloodstream infections in end-stage renal failure patients on haemodialysis: a case study. International Journal of Antimicrobial Agents, 2015, 46, 720-721.	2.5	2
29	Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria. Microorganisms, 2020, 8, 1489.	3.6	1
30	Outcomes on the Use of Daptomycin for the Treatment of Vancomycin-Resistant Enterococcal (VRE) Intra-abdominal Infections (IAI). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
31	Use of Ribavirin in Viral Respiratory Tract Infections in Singapore General Hospital. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
32	228. Impact of Early Alert to Antimicrobial Stewardship Interventions with the Prospective Audit and Feedback Strategy. Open Forum Infectious Diseases, 2018, 5, S98-S98.	0.9	0
33	187. Comparison of Active Versus Passive Strategies in Improving Compliance to Antimicrobial Stewardship Interventions. Open Forum Infectious Diseases, 2018, 5, S83-S83.	0.9	0
34	708. Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients. Open Forum Infectious Diseases, 2018, 5, S255-S255.	0.9	0